Brevan Howard Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Brevan Howard Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$253K	Buy	32,744 +8,064	+33%	+$58.8K	﹤0.01%	1743
2025 Q4	$151K	Sell	24,680 -3,416	-12%	-$36.9K	﹤0.01%	1632
2025 Q3	$518K	Buy	+28,096	New	+$451K	﹤0.01%	1273
2025 Q1	–	Sell	-12,305	Closed	-$209K	–	1150
2024 Q4	$209K	Buy	12,305 +1,486	+14%	+$28K	﹤0.01%	899
2024 Q3	$251K	Buy	+10,819	New	+$231K	﹤0.01%	923
2024 Q1	–	Sell	-6,749	Closed	-$213K	–	1002
2023 Q4	$213K	Buy	+6,749	New	+$160K	﹤0.01%	864

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brevan Howard Capital Management's ARCT Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Arcturus Therapeutics (ARCT) stake by 33% in Q1 2026, buying an estimated $58.8K and bringing the position to 32,744 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Brevan Howard Capital Management first reported a position in ARCT in Q4 2023 and has held it in 6 quarters since. The position peaked at $518K in Q3 2025. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

Brevan Howard Capital Management held 32,744 shares of Arcturus Therapeutics worth $253K as of Q1 2026.
Brevan Howard Capital Management bought 8,064 Arcturus Therapeutics shares in Q1 2026, an estimated $58.8K.
Arcturus Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1743 holding.
Brevan Howard Capital Management first reported a position in Arcturus Therapeutics in Q4 2023 and has held it in 6 quarters since.
Brevan Howard Capital Management's Arcturus Therapeutics position peaked at $518K in Q3 2025.
124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.